130 related articles for article (PubMed ID: 36521351)
1. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
Boone RM; Praiss AM; Huang Y; Melamed A; Khoury-Collado F; Hou JY; Gockley A; St Clair CM; Hershman DL; Wright JD
Gynecol Oncol; 2023 Feb; 169():70-77. PubMed ID: 36521351
[TBL] [Abstract][Full Text] [Related]
2. A proposal for a new classification of "unfavorable risk criteria" in patients with stage I endometrial cancer.
Li R; Shinde A; Han E; Lee S; Beriwal S; Harkenrider M; Kamrava M; Chen YJ; Glaser S
Int J Gynecol Cancer; 2019 Sep; 29(7):1086-1093. PubMed ID: 31474587
[TBL] [Abstract][Full Text] [Related]
3. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
4. Trends in use of radiation therapy, chemotherapy, and combination chemoradiotherapy in advanced uterine cancer before, during, and after GOG 258.
Lee SS; Weil CR; Boyd LR; DeCesaris C; Gaffney D; Suneja G
Int J Gynecol Cancer; 2023 Sep; 33(9):1408-1418. PubMed ID: 37487661
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
6. Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy.
Pendlebury A; Radeva M; Rose PG
J Surg Oncol; 2021 Apr; 123(5):1292-1298. PubMed ID: 33592112
[TBL] [Abstract][Full Text] [Related]
7. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary study of sequential multi-modality adjuvant chemotherapy and radiation for advanced endometrial cancer].
Zhang G; Suo HY; Shen XY; Zhao LJ; Wang ZQ; Kong WM; Li XP; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2019 Feb; 54(2):103-109. PubMed ID: 30803169
[No Abstract] [Full Text] [Related]
10. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
11. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
12. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study.
Forsse D; Barbero ML; Werner HMJ; Woie K; Nordskar N; Berge Nilsen E; Ellstrøm Engh M; Vistad I; Rege A; Sævik-Lode M; Andreasen S; Haldorsen IS; Trovik J; Krakstad C
Am J Obstet Gynecol; 2022 Jan; 226(1):90.e1-90.e20. PubMed ID: 34400137
[TBL] [Abstract][Full Text] [Related]
14. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
Bishop EA; Java JJ; Moore KN; Walker JL
Int J Gynecol Cancer; 2017 May; 27(4):730-737. PubMed ID: 28399028
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
Tatebe K; Hasan Y; Son CH
Gynecol Oncol; 2019 Dec; 155(3):429-435. PubMed ID: 31610885
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for advanced endometrial cancer.
Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
[TBL] [Abstract][Full Text] [Related]
17. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA
Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
Jamieson A; Huvila J; Leung S; Chiu D; Thompson EF; Lum A; Kinloch M; Helpman L; Salvador S; Vicus D; Kean S; Samouelian V; Grondin K; Irving J; Offman S; Parra-Herran C; Lau S; Scott S; Plante M; McConechy MK; Huntsman DG; Talhouk A; Kommoss S; Gilks CB; McAlpine JN
Gynecol Oncol; 2023 Mar; 170():282-289. PubMed ID: 36753816
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
20. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
